S 520: Ensures ovarian cancer survivors have the right to access screenings for health conditions.
The bill aims to ensure that ovarian cancer survivors have the right to access screenings for health conditions. No person with a personal history of ovarian cancer shall be denied genetic testing or genomic tumor profiling for inherited germline mutations and acquired somatic mutations. This testing should include genetic mutations in BRCA1 and BRCA2 genes, Lynch syndrome, and rearrangement analysis of all coding exons associated with ovarian cancer. Additionally, the bill allows for the inclusion of other medically necessary mutations as determined by the healthcare professional treating the individual. The bill takes effect immediately, providing ovarian cancer survivors with access to necessary screenings without restrictions.
| May. 29, 2026 | referred to health |
| May. 29, 2026 | DELIVERED TO ASSEMBLY |
| May. 29, 2026 | PASSED SENATE |
| May. 14, 2026 | ADVANCED TO THIRD READING |
| May. 13, 2026 | 2ND REPORT CAL. |
STATE OF NEW YORK ________________________________________________________________________ 520 2025-2026 Regular Sessions IN SENATE (Prefiled) January 8, 2025 ___________ Introduced by Sens. PERSAUD, BORRELLO, CLEARE, COMRIE, PALUMBO, ROLISON, WEBER, WEIK -- read twice and ordered printed, and when printed to be committed to the Committee on Women's Issues AN ACT to amend the public health law, in relation to ensuring ovarian cancer survivors have the right to access screenings for health condi- tions The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 2404-e to read as follows: 3 § 2404-e. Ovarian cancer; right to screenings. No person with a 4 personal history of ovarian cancer shall be denied genetic testing or 5 genomic tumor profiling for inherited germline mutations and acquired 6 somatic mutations, respectively. In general, such testing shall not be 7 subject to frequency caps or other limitations and shall include, but 8 not be limited to: 9 (a) genetic mutations in BRCA1 and BRCA2 genes; 10 (b) genetic mutations associated with Lynch syndrome; 11 (c) rearrangement analysis of all coding exons associated with ovarian 12 cancer; and 13 (d) additional mutations if medically necessary and appropriate, as 14 determined by the health care professional treating the individual. 15 § 2. This act shall take effect immediately. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD02193-01-5